The longstanding notion that head and neck squamous cell carcinoma (HNSCC) is a uniform disease process is changing. Divergence in epidemiologic trends among HNSCCs arising in different anatomic subsites has introduced a view that HNSCC is a heterogeneous group. Analysis of molecular genetic changes discloses not just individual tumor differences, but also consistent large-scale differences tha...

Antibody signatures may become sophisticated screening tools for early diagnosis and the development of personalized anticancer treatments. We used biopanning to enrich the immune response of head and neck squamous cell carcinoma (HNSCC) patients. This method revealed a HNSCC-specific antibody signature and allowed for the discovery of a novel oncogene, L23.

Head and neck squamous cell carcinoma (HNSCC) survival remains poor despite continuing efforts toward prevention, early detection, and improved treatment modalities. In part, this is thought to be due to a relative lack of molecular targeted therapeutic strategies beyond general mitosis inhibition, which sets a limit to what modern head and neck surgery can accomplish for advanced disease. The ...

BACKGROUND The correlation between podoplanin expression and extracapsular spread in head and neck squamous cell carcinoma (HNSCC) has never been reported. The purpose of this study was to assess the predictive value of podoplanin expression for this parameter. METHODS Subjective immunoreactivity scores and semiquantitative image analysis of podoplanin expression were performed in 67 patients...

Background Validated biomarkers in head and neck squamous cell carcinoma (HNSCC) are scarce. Methods We retrospectively analyzed 62 patients with HNSCC treated radiotherapy +/− concurrent chemotherapy. Pretreatment metabolic tumor volume (MTV) total lesion glycolysis (TLG) were measured a 18F-FDG positron emission tomography using liver dependent standardized uptake value threshold. Cox regress...

Submit Manuscript | http://medcraveonline.com Abbreviations: NDV: Newcastle Disease Virus; APMV-1: Avian Paramyxovirus Type I; IFN: Interferon; CTLA-4: Cytotoxic T Lymphocyte Associated Antigen-4; RCC: Renal Cell Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; IL-2: Interleukin-2; DTH: Delayed Type Hypersensitivity; Gy: Gray; BCG: Bacillus Calmette-Guerin; HN: Hemagglutinin-Neuraminida...

The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly mutated pathway in head and neck squamous cell carcinoma (HNSCC). There are several drugs targeting members of the PI3K signaling pathway in development for HNSCC. In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of t...

Background Immune suppression is one of the hallmarks by which head and neck squamous cell carcinoma (HNSCC) develops a tumor permissible environment[1]. Semaphorin 4D (Sema4D), known for its various developmental, physiological and pathological effects, was recently shown to play a role in regulating the immune system[2]. Sema4D is expressed in many epithelial tumors including HNSCC[3]; yet, t...